Wealth Enhancement Advisory Services LLC Has $1.08 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Wealth Enhancement Advisory Services LLC lessened its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 9.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,311 shares of the company’s stock after selling 2,930 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in CRISPR Therapeutics were worth $1,075,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in CRSP. Spire Wealth Management boosted its position in CRISPR Therapeutics by 303.7% during the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock valued at $78,000 after purchasing an additional 1,482 shares during the last quarter. Kestra Private Wealth Services LLC raised its stake in shares of CRISPR Therapeutics by 1.5% during the 4th quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company’s stock worth $812,000 after purchasing an additional 310 shares in the last quarter. Capital Advisors Inc. OK boosted its holdings in shares of CRISPR Therapeutics by 3.2% in the 4th quarter. Capital Advisors Inc. OK now owns 310,270 shares of the company’s stock valued at $12,212,000 after buying an additional 9,681 shares during the last quarter. Van ECK Associates Corp boosted its holdings in shares of CRISPR Therapeutics by 5,269.3% in the 4th quarter. Van ECK Associates Corp now owns 83,010 shares of the company’s stock valued at $3,267,000 after buying an additional 81,464 shares during the last quarter. Finally, Congress Asset Management Co. grew its stake in shares of CRISPR Therapeutics by 4.5% in the fourth quarter. Congress Asset Management Co. now owns 68,739 shares of the company’s stock valued at $2,706,000 after buying an additional 2,971 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insider Buying and Selling at CRISPR Therapeutics

In related news, COO Julianne Bruno sold 1,198 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $50,819.16. Following the transaction, the chief operating officer now directly owns 8,263 shares of the company’s stock, valued at approximately $350,516.46. This trade represents a 12.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Samarth Kulkarni sold 9,973 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $423,054.66. Following the completion of the sale, the chief executive officer now owns 180,890 shares of the company’s stock, valued at $7,673,353.80. This trade represents a 5.23% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 17,953 shares of company stock valued at $736,087 in the last ninety days. 4.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

CRSP has been the topic of several analyst reports. Stifel Nicolaus dropped their price target on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating on the stock in a research report on Thursday, February 13th. Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Wednesday, February 19th. Royal Bank of Canada cut their target price on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a research note on Wednesday, February 12th. Needham & Company LLC reiterated a “buy” rating and set a $81.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, May 20th. Finally, Wall Street Zen upgraded CRISPR Therapeutics to a “sell” rating in a research note on Friday, May 16th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, CRISPR Therapeutics has an average rating of “Hold” and a consensus target price of $71.75.

CRISPR Therapeutics Stock Up 8.5%

Shares of NASDAQ:CRSP opened at $41.86 on Monday. CRISPR Therapeutics AG has a 12-month low of $30.04 and a 12-month high of $67.88. The stock has a market cap of $3.62 billion, a PE ratio of -9.58 and a beta of 1.75. The business has a 50 day moving average of $36.83 and a 200-day moving average of $41.10.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. The business’s revenue for the quarter was up 71.6% on a year-over-year basis. During the same period last year, the firm earned ($1.43) EPS. Equities research analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.